EMRIS Pharma, the Recent Spin-off of Hadasit and Yissum, Launches the Development of a New Innovative topical drug for the Treatment of Skin Toxicities, Improving Treatment and Quality of Life for Cancer Patients

Posted on by

A novel approach to treating skin toxicities caused by EGFRi, based on a decade of research by leading Israeli cancer researchers JERUSALEM, June 8, 2023 /PRNewswire/ — Hadasit, and Yissum, has spun off EMRIS Pharma in collaboration with NGT Healthcare2 VC. EMRIS Pharma is pioneering…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.